NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for usage in veterinary and human health in India, Europe, the Asia Pacific, the United States, and internationally. The company offers animal health pharmaceutical ingredients, such as homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, rafoxanide, diminazene aceturate, s-methoprene, carprofen, diminazene diaceturate, ractopamine HCI, toltrazuril, decoquinate, amitraz, marbofloxacin, flunixin meglumine, praziquantel, fenbendazole, and xylazine hydrochloride. It also provides human health pharmaceutical ingredients, including nitazoxanide and atovaquone; and intermediates and specialty chemicals comprising 1,4,7-Trimethyl-1,4,7-Triazacylononane and N-ethyl glucamine. In addition, the company offers finished dosage forms, including diminazene aceturate granules and homidium chloride tablets. NGL Fine-Chem Limited was incorporated in 1981 and is based in Mumbai, India.
Metrics to compare | NGLF | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNGLFPeersSector | |
---|---|---|---|---|
P/E Ratio | 36.0x | 36.9x | −0.5x | |
PEG Ratio | −0.73 | 0.54 | 0.00 | |
Price/Book | 2.7x | 3.8x | 2.6x | |
Price / LTM Sales | 2.0x | 3.9x | 3.3x | |
Upside (Analyst Target) | - | 12.2% | 43.4% | |
Fair Value Upside | Unlock | 5.8% | 7.1% | Unlock |